Liposomal Curcumin for Treatment of Diseases

Abstract

The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.

What is claimed is: 
     
         1 . A composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids comprise between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic. 
     
     
         2 . The composition of  claim 1 , wherein at least a portion of the liposome is PEGylated. 
     
     
         3 . The composition of  claim 1 , wherein the composition comprises a DMPC/Chol/DMPE-PEG-2000 liposome at a ratio of between 90:10:2 (w/w) to 90:10:9 (w/w) and the curcuminoids; a DMPC/Chol/DSPE-PEG-2000 liposome at a ratio of between 90:10:2 (w/w) to 90:10:9 (w/w) and the curcuminoids; a DMPC/DMPE-PEG-2000 liposome at a ratio of between 90:10:2 (w/w) to 90:10:9 (w/w) and the curcuminoids; or a DMPC/DSPE-PEG-2000 liposome at a ratio of between 90:10:2 (w/w) to 90:10:9 (w/w) and the curcuminoid. 
     
     
         4 . The composition of  claim 1 , wherein the curcuminoid is administered in a dose of from about 0.01 mg/kg of the individual's body weight to about 500 mg/kg of the individual's body weight. 
     
     
         5 . The composition of  claim 1 , wherein the curcumin is selected from the group consisting of Ar-tumerone, methylcurcumin, demethoxy curcumin, bisdemethoxycurcumin, sodium curcuminate, dibenzoylmethane, acetylcurcumin, feruloyl methane, tetrahydrocurcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (curcumin1), 1,7-bis(piperonyl)-1,6-heptadiene-3,5-dione (piperonyl curcumin) 1,7-bis(2-hydroxy naphthyl)-1,6-heptadiene-2,5-dione (2-hydroxyl naphthyl curcumin) and 1,1-bis (phenyl)-1,3,8,10 undecatetraene-5,7-dione. 
     
     
         6 . A method of treating a malignant or a non-malignant proliferative disease, an autoimmune or auto-inflammatory disease, a degenerative disease, or a parasitic disease comprising providing a patient in need thereof with an effective amount of a curcuminoid:PEGylated-liposome effective to load curcumin into the liposome, wherein the liposome comprises a ratio of liposome to PEG comprises between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic. 
     
     
         7 . The method of  claim 6 , wherein the composition comprises a DMPC/Chol/DMPE-PEG-2000 liposome at a ratio of between 90:10:2 (w/w) to 90:10:9 (w/w) and the curcuminoids; a DMPC/Chol/DSPE-PEG-2000 liposome at a ratio of between 90:10:2 (w/w) to 90:10:9 (w/w) and the curcuminoids; a DMPC/DMPE-PEG-2000 liposome at a ratio of between 90:10:2 (w/w) to 90:10:9 (w/w) and the curcuminoids; or a DMPC/DSPE-PEG-2000 liposome at a ratio of between 90:10:2 (w/w) to 90:10:9 (w/w) and the curcuminoid. 
     
     
         8 . The method of  claim 6 , wherein the curcuminoid is administered in a dose of from about 0.01 mg/kg of the individual's body weight to about 500 mg/kg of the individual's body weight. 
     
     
         9 . The method of  claim 6 , wherein the malignant disease is selected from cancer of the skin, the GI-tract (esophagus, stomach, small and large intestines), the lungs, the liver, the pancreas, the brain, the breasts, the prostate, the uterine cervix and vagina, head and neck and components of the hematopoietic system (leukemias, lymphomas). 
     
     
         10 . The method of  claim 6 , wherein the non-malignant tissue proliferative disease comprises gastrointestinal polyp formation, multiple polyposis and neurofibromatosis. 
     
     
         11 . The method of  claim 6 , wherein the autoimmune or anti-inflammatory comprises anaphylaxis, arthritis, or irritable bowel syndrome. 
     
     
         12 . The method of  claim 6 , wherein the neurodegenerative disease comprises fronto-temporal dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, carpal tunnel syndrome and amyotrophic lateral sclerosis (ALS). 
     
     
         13 . The method of  claim 6 , wherein the degenerative disease of the soft-tissue comprises cataracts, arthritis, neural disease, muscular disease, connective tissue disease, iron overload or hemochromatosis. 
     
     
         14 . The method of  claim 6 , wherein the curcumin is selected from the group consisting of Ar-tumerone, methylcurcumin, demethoxy curcumin, bisdemethoxycurcumin, sodium curcuminate, dibenzoylmethane, acetylcurcumin, feruloyl methane, tetrahydrocurcumin, 1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (curcumin1), 1,7-bis(piperonyl)-1,6-heptadiene-3,5-dione (piperonyl curcumin) 1,7-bis(2-hydroxy naphthyl)-1,6-heptadiene-2,5-dione (2-hydroxyl naphthyl curcumin) and 1,1-bis(phenyl)-1,3,8,10 undecatetraene-5,7-dione. 
     
     
         15 . The method of  claim 6 , wherein the parasitic infection is treated by contacting the parasite with an effective amount of a curcuminoid:liposome complex effective to treat the parasitic infection and the curcuminoids are selected from the group consisting of Ar-tumerone, methylcurcumin, demethoxy curcumin, bisdemethoxycurcumin, sodium curcuminate, dibenzoylmethane, acetylcurcumin, feruloyl methane, tetrahydrocurcumin, 1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (curcumin1), 1,7-bis(piperonyl)-1,6-heptadiene-3,5-dione (piperonyl curcumin) 1,7-bis(2-hydroxy naphthyl)-1,6-heptadiene-2,5-dione (2-hydroxyl naphthyl curcumin) and 1,1-bis(phenyl)-1,3,8,10 undecatetraene-5,7-dione. 
     
     
         16 . The method of  claim 15 , wherein the parasitic infection comprises  falciparum  hookworm, filiariais, Leishmaniasis,  Treponema,  Shistosomaisis. 
     
     
         17 . The method of  claim 15 , wherein the complex further comprises an anti-malarial agent selected from artesiminin, 8-aminoquinoline, amodiaquine, arteether, artemether, artemsinin, artesunate, artesunic acid, artelinic acid, atovoquone, azithromycine, biguanide, chloroquine, chloroquine phosphate, chlorproguanil, cycloguanil, dapsone, desbutyl halofantrine, desipramine, doxycycline, dihydrofolate, reductase inhibitors, dipyridamole, halofantrine, haloperidol, hydroxychloroquine sulfate, imipramine, mefloquine, penfluridol, phospholipid inhibitors, primaquine, proguanil, pyrimethamine, pyronaridine, quinine, quinidine, quinacrineartemisinin, sulfonamides, sulfones, sulfadoxine, sulfalene, tafenoquine, tetracycline, tetrandine, triazine, salts and derivatives thereof. 
     
     
         18 . A method of treating a non-human animal comprising: providing the non-human animal with an effective amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids comprises between 2 to 9 weight percent of the total composition effective to treat the non-human animal and the curcuminoids are natural or synthetic and the curcuminoid:liposome complex is PEGylated, wherein the curcuminoid is selected from the group consisting of Ar-tumerone, methylcurcumin, demethoxy curcumin, bisdemethoxycurcumin, sodium curcuminate, dibenzoylmethane, acetylcurcumin, feruloyl methane, tetrahydrocurcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (curcumin1), 1,7-bis(piperonyl)-1,6-heptadiene-3,5-dione (piperonyl curcumin) 1,7-bis(2-hydroxy naphthyl)-1,6-heptadiene-2,5-dione (2-hydroxyl naphthyl curcumin) and 1,1-bis(phenyl)-1,3,8,10 undecatetraene-5,7-dione. 
     
     
         19 . The method of  claim 18 , wherein the curcuminoid:liposome complex comprises sterically-stabilized liposomes. 
     
     
         20 . The method of  claim 18 , wherein the non-human animal comprises a horse, a cat, a dog, a hamster, a pig, a cow, a goat or a non-domesticated animal.